Lv4
510 积分 2023-11-27 加入
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
13天前
已完结
Rational Design of a Multifunctional Copper‐Cobalt Sulfide Nanozyme for Cholesterol Depletion and Thermo‐Resistant Tumor Ablation
2个月前
已完结
CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer
2个月前
已完结
Reprogramming T cell stemness against cancer
2个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
5个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
5个月前
已完结
皖公网安备34019202002308
